SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as investors monitor its resilience amid macroeconomic volatility and ongoing debates surrounding the impact of potential tariff refunds on retail pricing. The community remains focused on Costco's defensive strengths, with frequent discussions centered on its robust membership renewal rates, traffic growth, and valuation relative to the broader consumer staples sector.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for the community due to renewed institutional interest, shifting ecosystem management, and ongoing discussions regarding its quantum-resistant technology. While some traders debate the asset's long-term viability following historic price volatility, active participants are heavily focused on potential regulatory catalysts and the ongoing expansion of its real-world asset (RWA) utility.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is generating significant investor interest driven by high trading volumes, active momentum in its clinical-stage pipeline, and multiple analyst endorsements from firms like Guggenheim and HC Wainwright. Community discussion is focused on the high-stakes Phase 2 LOTUS trial readout expected in 2026 and ongoing debates regarding the company's financial risk profile versus the potential upside of its immunology platform.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community speculates on a major upcoming partnership announcement, with many pointing to a connection with Stellar or a potential collaboration with Ripple/XRP at an upcoming industry event. Investors are actively debating the project's long-term utility in global payroll and real-world adoption, balancing high-conviction sentiment against skepticism regarding its price performance and market volatility.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF is capturing investor attention as they rotate toward defensive, value-oriented positions amidst broader market volatility. The community is actively debating the fund's resilience, with many investors maintaining a long-term 'buy and hold' strategy despite recent stagnant performance, while others monitor the ETF's sector diversification and dividend growth potential as a reliable hedge.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is trending as the community eagerly awaits definitive biomarker data and regulatory updates regarding an accelerated approval pathway for its ALS candidate, CNM-Au8. Investors are closely monitoring upcoming conference presentations and regulatory milestones, balancing high-conviction long-term sentiment against volatility driven by short interest and recent insider selling activity.

BtcUSD is a completely decentralized stablecoin issued and managed by BTCFi, a platform where users can deposit Bitcoin of various formats to use as collaterals. BtcUSD offers Bitcoin holders the opportunity to generate additional yields with their Bitcoin positions through DeFi usage.

Bitcoin USD (BTCFi)

Bitcoin is experiencing heightened volatility and intense community debate as it tests critical support levels around 60k-65k, with traders closely monitoring technical formations like bear flags and head-and-shoulders patterns. While some bulls are looking for a reclaim of key resistance zones to trigger a long-term uptrend, many participants remain cautious, pointing to equity market weakness and potential liquidity risks that could lead to further downside tests.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is currently a focal point for the community due to major structural updates like Mission 70aimed at reducing token inflationand increasing adoption through sovereign subnets in regions like Switzerland and Pakistan. While some users remain skeptical due to historical volatility and the project's long-term performance, many community members are highlighting the real-world utility of platforms like Caffeine.ai and the growing number of canisters as indicators that the network's fundamentals are strengthening for a future recovery.

Provides investment banking, securities and asset management services

Goldman Sachs Group, Inc.

Goldman Sachs is capturing significant attention as the firm integrates advanced AI models to automate compliance roles, while simultaneously navigating heightened market scrutiny over its past ties to Jeffrey Epstein and recent leadership resignations. The stock is experiencing intense volatility as investors weigh these corporate headwinds against the firm's strategic expansion into private credit and asset management.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox (BW) is experiencing significant momentum following a major $2.4 billion power infrastructure contract, with community discussions largely focused on its role in providing essential energy solutions for AI data centers. The stock is a primary focal point for investors tracking related holdings like B. Riley (RILY) and Applied Digital (APLD), as participants debate the impact of institutional backing and the potential for a long-term valuation re-rating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Pfizer reported positive Phase 2b topline results for its GLP-1 candidate in adults with obesity or overweight without type 2 diabetes.</li><li>The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.</li><li>For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data.</li></ul>Pfizer Inc. (PFE) stock was in the spotlight on Tuesday after the company reported positive updates from a study testing weight loss treatment and a better-than expected fourth quarter print.However, <a href="https://stocktwits.com/symbol/PFE">PFE shares</a> were down 2% in pre-market trading on Tuesday as investors appeared to remain cautious about growth risks and the long road ahead for its GLP-1 pipeline.&nbsp;<h2 class="st-heading-2">Positive Topline Results For Weight Loss Treatment&nbsp;</h2>Pfizer reported positive topline results from its Phase 2b VESPER-3 study evaluating PF’3944, an ultra-long-acting injectable GLP-1 receptor agonist, in adults with obesity or overweight without type 2 diabetes.The trial aimed to determine whether patients could maintain weight loss while switching from weekly to once-monthly injections and whether the treatment would retain a favorable safety profile.The study met its primary endpoint, delivering statistically significant weight reduction across all tested doses. Participants achieved up to 12.3% mean placebo-adjusted weight loss at week 28. PF’3944 was generally well tolerated, with mostly mild to moderate gastrointestinal side effects and limited treatment discontinuations. The safety profile remained consistent with the broader GLP-1 drug class.“Based on the monthly dosing efficacy and tolerability demonstrated in this trial, we remain confident in our plan to include a higher 9.6 mg monthly maintenance dose of PF’3944 in Phase 3,” said Jim List, Chief Internal Medicine Officer.Following its acquisition of Metsera and a global licensing deal with YaoPharma, Pfizer said it is accelerating its obesity treatment pipeline. The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.<h2 class="st-heading-2">Q4 Earnings Snapshot</h2>Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted diluted earnings between $2.80 and $3 per share. The company said the outlook includes roughly $5 billion in expected COVID-19 product sales and a projected $1.5 billion year-over-year revenue hit from certain products losing exclusivity.The company posted a 2% decline in FY2025 revenue at $62.6 billion with adjusted earnings of $3.22 per share.For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data. It also posted a better-than-expected EPS of $0.66.<h2 class="st-heading-2">What Did Stocktwits Users Say?</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes. PFE was among the top trending tickers on the platform.<figure class="image"><img src="https://news.stocktwits-cdn.com/PFE_jpg_91e98a5cdf.webp" alt="PFE.jpg" width="928" height="111"><figcaption>PFE's Sentiment Meter and Message Volumes in Pre-Market on Feb. 3, 2026 | Source: Stocktwits</figcaption></figure>One user expects multiple upcoming catalysts this year for the stock.<stembedurl>https://stocktwits.com/giuseppe8469/message/643776399</stembedurl>Another user highlighted key support and resistance levels.<stembedurl>https://stocktwits.com/Jas45z/message/643776263</stembedurl>The stock has gained around 1.5% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-pre-market-what-moving-average-indicates/cZbiqlvR4ln">SOFI Stock Hovers Around 200-DMA — A Make-or-Break Test Looms</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Reports Positive Weight-Loss Trial Results, Strong Q4 – So Why Is PFE Stock Falling?

Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion, while its FY2025 revenue came in at $62.6 billion.

Equity

Pharma ETF (FTXH) Hits New 52-Week High

Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.



Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month 

As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.  

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.


What Are Wall Street Analysts' Target Price for Bristol-Myers Squibb Stock?

Pharma giant Bristol-Myers Squibb has notably outpaced the broader pharma industry over the past year and analysts remain moderately bullish on the stock’s prospects.

First Trust Exchange-Traded Fund VI - First Trust Nasdaq Pharmaceuticals ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

FTXH
First Trust Exchange-Traded Fund III - First Trust Nasdaq Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FTXH News

FTXHFirst Trust Exchange-Traded Fund III - First Trust Nasdaq Pharmaceuticals ETF